- Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care’s commitment to improving patient outcomes.
- Top Abstract recognition for “Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort,” presented in the “Dialysis” category.
- CONVINCE trial analysis links hemodiafiltration to slower health decline and better quality of life in key dialysis patient groups.
Bad Homburg, May 30, 2025 – Fresenius Medical Care (FME), the world’s leading provider of products and services for individuals with renal diseases, presents new research and innovations at the 62nd Congress of the European Renal Association (ERA), June 4-7 in Vienna, Austria highlighting the company’s growing emphasis on data-driven insights and real-world evidence to advance patient care and improve outcomes and quality of life for people with kidney disease worldwide.
"Our highlighted research demonstrates our continued drive to innovate in kidney care,” said Frank Maddux, MD, Global Chief Medical Officer at Fresenius Medical Care AG. “To further enhance our commitment to improving patient outcomes globally, our latest work focuses on Home, Critical Care and In-Center HD, and high-volume hemodiafiltration in particular. ERA is an essential platform to reinforce collaboration and drive the future of nephrology."
Fresenius Medical Care’s Global Medical Office and the company’s kidney disease think tank, the Renal Research Institute (RRI), present 52 abstracts spanning critical areas of nephrology, including critical care, fluid management, hemodiafiltration (HDF), and the use of artificial intelligence (AI) in patient care.
Key presentations include:
- Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort: Awarded Top Abstract for Young Authors in the “Dialysis” category, this study, authored by RRI’s Andrea Nandorine Ban, uses AI to evaluate patterns of arterial oxygen saturation during dialysis, highlighting the prevalence of intradialytic hypoxemia and its potential link to sleep apnea.
- Health Status in Different Subgroups of People Receiving Hemodiafiltration Versus Hemodialysis for Renal Replacement Therapy: A subgroup analysis of the CONVINCE randomized controlled trial examines whether the slower decline in self-reported health status with hemodiafiltration (HDF) versus hemodialysis (HD) varies by age, sex, dialysis vintage, diabetes, cardiovascular disease, and vascular access type. Results highlight particular improvements in physical and cognitive function, pain interference, and social participation with HDF.
- Impact of Fluid Overload Changes Within the First Six Months of Dialysis on Hospitalization During a Two-year Follow-up: Using data collected from the Body Composition Monitor, a validated whole-body bioimpedance spectroscopy device, this study evaluates how early changes in fluid overload in hemodialysis (HD) and HDF patients are associated with hospitalization risk over a two-year period.
- Delivered Hemodialysis Treatment Time and Mortality Risk: A Retrospective Analysis: Shorter treatment times have been shown to increase mortality in hemodialysis (HD) patients. This analysis reinforces treatment time as a modifiable factor and encourages clinical teams to optimize therapy durations to improve survival outcomes for HD patients.
- Novel AI-Based Recipe Recommendation System for Dialysis Patients Using Retrieval-Augmented Generation: Leveraging Retrieval-Augmented Generation and OpenAI models, this innovation provides dialysis patients with personalized, scalable dietary recommendations, supporting better nutritional management.
In addition to these presentations, FME leaders and researchers will also be available onsite at Booth #460 to discuss research insights, clinical collaborations, and innovations in kidney care.
To learn more about FME’s presence at ERA, please click here.
About Fresenius Medical Care:
Fresenius Medical Care is the world's leading provider of products and services for individuals with renal diseases of which around 4.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,674 dialysis clinics, Fresenius Medical Care provides dialysis treatments for approx. 299,000 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS).
The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission’s opinions.
The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).
Disclaimer:
This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. These and other risks and uncertainties are detailed in Fresenius Medical Care’s reports filed with the U.S. Securities and Exchange Commission. Fresenius Medical Care does not undertake any responsibility to update the forward-looking statements in this release.
